Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - - Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated -
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - - Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated -
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.